Tectonic Therapeutic annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tectonic Therapeutic Free Cash Flow (FCF) History (TECX)
Tectonic Therapeutic reported −$60.3M in free cash flow for fiscal 2025, a decrease of $1.1M from the previous fiscal year.
View full Tectonic Therapeutic company overviewTectonic Therapeutic free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$60.3M | −$1.1M | — | — |
| 2024 | 2024-12-31 | −$59.2M | −$18.3M | — | — |
| 2023 | 2023-12-31 | −$41.0M | $56.5M | — | — |
| 2022 | 2022-12-31 | −$97.5M | $3.0M | — | — |
| 2021 | 2021-12-31 | −$100.5M | −$506,000 | — | — |
| 2020 | 2020-12-31 | −$100.0M | −$30.7M | — | — |
| 2019 | 2019-12-31 | −$69.3M | −$29.8M | — | — |
| 2018 | 2018-12-31 | −$39.5M | −$22.7M | — | — |
| 2017 | 2017-12-31 | −$16.8M | — | — | — |
Tectonic Therapeutic quarterly free cash flow
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$21.5M | −$6.8M | — | — |
| Q1 2026 | 2026-03-31 | −$18.4M | −$5.3M | — | — |
| Q4 2025 | 2025-12-31 | −$14.5M | $2.4M | — | — |
| Q3 2025 | 2025-09-30 | −$18.0M | $1.8M | — | — |
| Q2 2025 | 2025-06-30 | −$14.7M | −$1.3M | — | — |
| Q1 2025 | 2025-03-31 | −$13.1M | −$3.8M | — | — |
| Q4 2024 | 2024-12-31 | −$16.8M | −$5.1M | — | — |
| Q3 2024 | 2024-09-30 | −$19.8M | −$11.3M | — | — |
| Q2 2024 | 2024-06-30 | −$13.4M | −$12.9M | — | — |
| Q1 2024 | 2024-03-31 | −$9.3M | $11.0M | — | — |
| Q4 2023 | 2023-12-31 | −$11.7M | $12.0M | — | — |
| Q3 2023 | 2023-09-30 | −$8.5M | $8.0M | — | — |
| Q2 2023 | 2023-06-30 | −$473,000 | $28.8M | — | — |
| Q1 2023 | 2023-03-31 | −$20.3M | $7.8M | — | — |
| Q4 2022 | 2022-12-31 | −$23.7M | $3.1M | — | — |
| Q3 2022 | 2022-09-30 | −$16.5M | $8.6M | — | — |
| Q2 2022 | 2022-06-30 | −$29.3M | −$8.1M | — | — |
| Q1 2022 | 2022-03-31 | −$28.0M | −$592,000 | — | — |
| Q4 2021 | 2021-12-31 | −$26.7M | $3.8M | — | — |
| Q3 2021 | 2021-09-30 | −$25.1M | −$197,000 | — | — |
| Q2 2021 | 2021-06-30 | −$21.2M | $312,000 | — | — |
| Q1 2021 | 2021-03-31 | −$27.5M | −$4.4M | — | — |
| Q4 2020 | 2020-12-31 | −$30.6M | −$11.2M | — | — |
| Q3 2020 | 2020-09-30 | −$24.9M | −$11.4M | — | — |
| Q2 2020 | 2020-06-30 | −$21.5M | −$3.1M | — | — |
| Q1 2020 | 2020-03-31 | −$23.0M | −$4.9M | — | — |
| Q4 2019 | 2019-12-31 | −$19.3M | −$7.4M | — | — |
| Q3 2019 | 2019-09-30 | −$13.5M | −$560,000 | — | — |
| Q2 2019 | 2019-06-30 | −$18.4M | −$10.0M | — | — |
| Q1 2019 | 2019-03-31 | −$18.1M | −$11.8M | — | — |
| Q4 2018 | 2018-12-31 | −$11.9M | — | — | — |
| Q3 2018 | 2018-09-30 | −$12.9M | −$9.6M | — | — |
| Q2 2018 | 2018-06-30 | −$8.4M | — | — | — |
| Q1 2018 | 2018-03-31 | −$6.2M | — | — | — |
| Q3 2017 | 2017-09-30 | −$3.3M | — | — | — |
Tectonic Therapeutic free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$100.0M to −$60.3M, a net increase of $39.7M. Tectonic Therapeutic's latest reported quarter, Q2 2026, generated −$21.5M in free cash flow, a decrease of $6.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tectonic Therapeutic source filings ↗Community posts
Tectonic reports early safety data for vascular-disease antibody
Tectonic Therapeutic ($TECX) reported favorable Phase Ia safety findings for TX2100, an experimental antibody being developed for hereditary hemorrhagic telangiectasia, an inherited vascular disorder. Across six single-dose cohorts in healt ...
